2024-03-28T18:47:30Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_F6160457AF7A
2024-03-23T03:12:56Z
serval:BIB_F6160457AF7A
Current status of immune checkpoint inhibition in early-stage NSCLC.
10.1093/annonc/mdz175
000493072600009
31143921
Vansteenkiste
J.
author
Wauters
E.
author
Reymen
B.
author
Ackermann
C.J.
author
Peters
S.
author
De Ruysscher
D.
author
article
2019-08-01
Annals of oncology
1569-8041
0923-7534
journal
30
8
1244-1253
Antineoplastic Agents, Immunological/pharmacology
Antineoplastic Agents, Immunological/therapeutic use
B7-H1 Antigen/antagonists & inhibitors
B7-H1 Antigen/immunology
Carcinoma, Non-Small-Cell Lung/immunology
Carcinoma, Non-Small-Cell Lung/mortality
Carcinoma, Non-Small-Cell Lung/pathology
Carcinoma, Non-Small-Cell Lung/therapy
Chemoradiotherapy, Adjuvant/methods
Clinical Trials as Topic
Humans
Lung Neoplasms/immunology
Lung Neoplasms/mortality
Lung Neoplasms/pathology
Lung Neoplasms/therapy
Neoadjuvant Therapy/methods
Neoplasm Recurrence, Local/immunology
Neoplasm Recurrence, Local/pathology
Neoplasm Recurrence, Local/prevention & control
Pneumonectomy
Programmed Cell Death 1 Receptor/antagonists & inhibitors
Programmed Cell Death 1 Receptor/immunology
Progression-Free Survival
Radiosurgery
clinical trials
early stage
immunotherapy
non-small-cell lung cancer
eng
60_published
true
peer-reviewed
Publication types: Journal Article ; Review
Publication Status: ppublish